DURECT (DRRX) Competitors $0.59 -0.02 (-3.56%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. IZTC, OCX, ADAG, CRVO, TCRX, IMAB, JMAC, INZY, CRBU, and ADAPShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), TScan Therapeutics (TCRX), I-Mab (IMAB), Maxpro Capital Acquisition (JMAC), Inozyme Pharma (INZY), Caribou Biosciences (CRBU), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Invizyne Technologies OncoCyte Adagene CervoMed TScan Therapeutics I-Mab Maxpro Capital Acquisition Inozyme Pharma Caribou Biosciences Adaptimmune Therapeutics Invizyne Technologies (NASDAQ:IZTC) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking. Is IZTC or DRRX more profitable? Invizyne Technologies has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Invizyne Technologies' return on equity of 0.00% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A DURECT -198.58%-300.62%-65.17% Does the media prefer IZTC or DRRX? In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled DURECT'saverage media sentiment score. Company Overall Sentiment Invizyne Technologies Neutral DURECT Neutral Which has higher earnings & valuation, IZTC or DRRX? Invizyne Technologies has higher earnings, but lower revenue than DURECT. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/ADURECT$1.86M9.84-$27.62M-$0.15-3.92 Do analysts rate IZTC or DRRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor IZTC or DRRX? DURECT received 316 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformInvizyne TechnologiesN/AN/ADURECTOutperform Votes31660.89% Underperform Votes20339.11% Do institutionals & insiders have more ownership in IZTC or DRRX? 28.0% of DURECT shares are held by institutional investors. 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryDURECT beats Invizyne Technologies on 5 of the 8 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.94M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.968.9226.8419.71Price / Sales9.84253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.186.466.794.50Net Income-$27.62M$143.98M$3.23B$248.18M7 Day Performance-4.73%2.03%1.53%0.20%1 Month Performance-19.54%4.11%10.06%12.37%1 Year Performance-52.16%-2.87%16.72%7.04% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT0.178 of 5 stars$0.59-3.6%N/A-54.4%$18.94M$1.86M-0.9680Analyst ForecastGap DownHigh Trading VolumeIZTCInvizyne TechnologiesN/A$13.01+4.0%N/AN/A$81.34MN/A0.00N/AOCXOncoCyte2.414 of 5 stars$2.81-2.1%$4.42+57.2%+8.9%$80.36M$1.88M-0.64120Analyst ForecastGap DownADAGAdagene2.3111 of 5 stars$1.70+6.2%$8.00+370.9%-35.9%$80.04M$103,204.000.00260Positive NewsGap UpCRVOCervoMed3.3131 of 5 stars$9.10+7.2%$27.63+203.6%-56.2%$79.20M$7.14M-4.484TCRXTScan Therapeutics3.9397 of 5 stars$1.37+7.9%$8.50+520.4%-85.8%$77.53M$4.42M-1.29100Positive NewsInsider TradeIMABI-Mab3.1868 of 5 stars$0.95+7.4%$5.50+482.0%-46.4%$77.02M$3.27M0.00380News CoverageJMACMaxpro Capital AcquisitionN/A$5.68flatN/A+1,580.3%$76.27MN/A0.002,021Gap UpINZYInozyme Pharma2.8803 of 5 stars$1.18+2.6%$14.63+1,139.4%-16.0%$76.18MN/A-0.7650CRBUCaribou Biosciences2.892 of 5 stars$0.82+5.7%$9.33+1,040.9%-67.2%$76.09M$9.99M-0.50100ADAPAdaptimmune Therapeutics2.7359 of 5 stars$0.30+0.9%$1.83+519.9%-74.5%$75.94M$178.03M-1.34490 Related Companies and Tools Related Companies IZTC Competitors OCX Competitors ADAG Competitors CRVO Competitors TCRX Competitors IMAB Competitors JMAC Competitors INZY Competitors CRBU Competitors ADAP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRRX Stock Free DRRX Stock Alerts